Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 751 - 800 out of 6,212

Document Document Title
WO/2004/007459A2
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatme...  
WO/2004/007407A2
The present invention includes methods and compositions for increasing the fluorous nature of an organic compound by reacting it with at least one fluorous compound to produce a fluorous tagged organic compound. The increased fluorous na...  
WO/2004/007436A1
The invention relates to a method for producing tetra-substituted ureas by reacting the corresponding amines with phosgene in the presence of an aqueous inorganic base at a temperature ranging of from 0 to 150 °C. According to the inven...  
WO/2004/005478A2
This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA cons...  
WO/2004/002941A1
The invention concerns cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and their salts. The invention also concerns the method for preparing same and use thereof for reducing pigmentation.  
WO/2004/002944A1
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.  
WO/2004/002940A1
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.  
WO/2004/000295A1
A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH2...  
WO/2003/105846A1
The present invention relates to compounds of formula I, wherein X, Q, W, R1, R2 and R3 are as defined in the claims, which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. T...  
WO/2003/103651A1
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for...  
WO/2003/104188A1
The invention relates to N-benzoylureidocinnamate derivatives of formula (I), where R1-R11 have the meanings given in the claims, the physiologically acceptable salts and method for production thereof. The compounds are suitable as anti-...  
WO2003072537A3
Compounds of formula (I), or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the ...  
WO/2003/101927A1
Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A...  
WO2002008174A8
Novel mono- and dihydroxy phenylethylamine derivatives useful in treating melanoma are provided having the formulae (Ia, Ib or Ic). In the above formulae, R is hydrogen or -COOR, R is hydrogen or C1-6 alkyl; R and R independently represe...  
WO2003004460A3
The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment ...  
WO/2003/102592A2
There is disclosed a method for selectively binding micromolecules having a lysine functionality comprising the steps of: providing a sample containing one or more species of macromolecules, each having a lysine functionality; providing ...  
WO/2003/102044A2
Low-cure powder coating compositions are disclosed. The compositions comprise a polyepoxide and a material having the structure: formula (I) wherein R1 is an organic radical having 6 to 25 carbon atoms; R2 is an organic radical having 1 ...  
WO2003034989A3
Acylated alpha -hydroxyarylbutanamines and related sulfonamides, ureas and carbamates that inhibit aspartyl protease are disclosed, as are methods of treating diseases, particularly HIV, using these compounds. The compounds have the form...  
WO/2003/099776A1
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...  
WO2003057169A3
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infect...  
WO2003014064A8
Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R<6>, R<7>, ...  
WO/2003/097586A1
This invention is directed to vanilloid receptor VR1 ligands of formula (1). More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment an...  
WO/2003/097587A2
The invention relates to a novel class of gelling agents, to a process of preparing said agents, to the use of said agents to prepare gels, and to the gels thus obtained. A gelling agent or thickener according to the invention comprises ...  
WO2002057242A3
Novel antagonists of alpha4beta1 integrin and/or alpha4beta7 integrin of the general Formula (I): wherein R1, R2, R5, L1, L2, Rb, W and Z are as defined in any one of claims 1 to 13, A represents -CH- or a nitrogen atom, and p is from 0 ...  
WO/2003/097619A1
A novel class of compounds of the general formula (I), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the...  
WO2002002506A8
The present invention is substituted amines of formula (XV) useful in treating Alzheimer's disease and other similar diseases.  
WO2003051276A3
Compounds of formula (I) or (II) wherein R ¿1? , R ¿2? , R ¿3? , R ¿4? , W, Q, G, X and Y are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared...  
WO/2003/095438A1
Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.  
WO/2003/095420A1
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...  
WO2002002505A8
The present invention is substituted amines of formula (X) useful in treating Alzheimer's disease and other similar diseases.  
WO/2003/092670A1
Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein teh substituents have the values mentioned herein, are bombesin antagonists, which have utility in variety of therapeutic areas including male and female sexual...  
WO2001040188A8
The present invention is directed to curcumin analogs (I), wherein Y is OH, halogen, or CF3; Z is H, OH, OR1, halogen, or CF3; X1 and X2 are independently C or N; and A is as defined in the application; exhibiting anti-tumor and anti-ang...  
WO2002002520A8
The present invention is disubstituted amines of formula (I) and disubstituted amines of formula (II) useful in treating Alzheimer's disease and other similar diseases.  
WO2003024448A3
The invention relates to the inhibition of histone deacetylase. The invention provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell p...  
WO2002098849A3
Disclosed are compounds of formula X, where R¿n<, R¿20?, R¿1?, R¿2?, R¿3?, and R¿c? are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising c...  
WO/2003/093250A2
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases...  
WO/2003/093224A1
Compounds of the formula (R5)m-(R6A)-2-(R4)-1-[N= C(R1)N(R2)(R3)]benzene and their agriculturally suitable salts, are disclosed which are useful as fungicides, wherein R1 is H, OH, SH, SO3H, CN, -OR7 or -SR7; C1-C10 alkyl, C2-C10 alkenyl...  
WO2003066889A3
This invention is directed to a continuous method for measuring the activity of an enzyme that catalyzes the addition of an acetyl group to a residue capable of being acetylated or an enzyme that catalyzes the removal of an acetyl group ...  
WO/2003/091204A1
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...  
WO/2003/091287A1
Compounds of formula (I), wherein Y is, for example, C3-C,12alkylene, butenylene, butynylene, or C4-C,12alkylene interrupted one or more times by non-consecutive -O- or -NR2-; R1 is a reactive group selected from OH, SH, NR3R4, -(CO)-OH,...  
WO2003066579A3
The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical c...  
WO/2003/089404A1
The present invention relates to naphthylamide compounds and their ability to act as potassium channel openers.  
WO/2003/089615A2
Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a com...  
WO/2003/089405A1
The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphoc...  
WO/2003/088915A2
The present invention is directed to novel phenytoin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and/o...  
WO/2003/087045A1
Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the c...  
WO2003055848A3
This invention relates to urea derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof: (I) wherein Y is R<1>- R<6> and X have the same meanings given in the description, which is useful as an active ingr...  
WO/2003/087044A2
Novel compounds of formula (I) which modulate MCH activity are disclosed, in which A is a linker; B is a connecting moiety; Ar1 and Ar2 are aryl or heteroaryl groups; R1 and R2 are hydrogen, halogen atoms, CF3, OCF3, SCF3, SCH3, nitrile,...  
WO/2003/087046A1
Novel compounds of formula (I) which modulate MCH activity are disclosed in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 and R2 are hydrogen, straight or branched alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylc...  
WO/2003/084997A1
Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more deta...  

Matches 751 - 800 out of 6,212